Zydus Lifesciences settles Mirabegron patent dispute with Astellas for $120 million
The Hindu - Business Line
Zydus Lifesciences will pay Astellas Pharma $120 million and ongoing licensing fees to settle a US patent dispute over the bladder drug Mirabegron.Summary
Zydus Lifesciences announced a $120 million settlement with Astellas Pharma to resolve a US patent dispute concerning the bladder disorder drug Mirabegron. In addition to the upfront payment, Zydus and its US unit will pay a pre-paid per-unit licensing fee on sales of its generic version of Mirabegron in the US until September 2027. The agreement resolves the dispute and allows Zydus to continue marketing its generic version of the drug under the terms of the settlement.
(Source：The Hindu - Business Line)